Autosomal Dominant Hyperinsulinism Due to SUR1 Deficiency

Autosomal dominant hyperinsulinism due to SUR1 deficiency is a genetic condition where the pancreas makes too much insulin even when the blood sugar is already low. “Autosomal dominant” means a single changed copy of the ABCC8 gene (which codes for the SUR1 part of the KATP channel) can cause the disease. When SUR1 does not work properly, the KATP channel in beta cells stays too closed, calcium flows in, and insulin is released at the wrong time. This drives blood sugar down, sometimes to dangerous levels. Many families have mild to moderate, often diazoxide-responsive hypoglycemia, but the severity can vary. MedlinePlus+2Orpha+2  The KATP channel is a “metabolic brake.” It senses energy in the cell and tells beta cells when to stop or start insulin. SUR1 (ABCC8) is one subunit of that channel. If SUR1 is faulty, the brake fails and insulin secretion becomes “stuck on,” especially during fasting or illness. MedlinePlus

Autosomal dominant hyperinsulinism due to SUR1 deficiency is a genetic form of low blood sugar (hypoglycemia) caused by pathogenic variants in the ABCC8 gene, which encodes the SUR1 subunit of the pancreatic K_ATP channel. Faulty SUR1 keeps these channels too closed, so beta cells release too much insulin even when blood sugar is already low. In dominantly inherited ABCC8 disease, symptoms are often milder and more responsive to the medicine diazoxide than in recessive K_ATP forms, though some dominant mutations can still be severe. NCBI+2BioMed Central+2

Normally, K_ATP channels let potassium flow out of beta cells and “tell” the cell whether glucose is high or low. With SUR1 deficiency, the channel is less open. The cell becomes too electrically active and leaks insulin even when sugar is low, causing repeated hypoglycemia. Dominant ABCC8 variants often leave some channel function (so symptoms can be milder and diazoxide may work), but not always. NCBI+1

---

Other names

Doctors and resources may use several names for the same disorder. You might see: “Autosomal dominant hyperinsulinism due to SUR1 deficiency,” “ABCC8-related autosomal dominant hyperinsulinism,” “diazoxide-sensitive diffuse hyperinsulinism (ABCC8),” or “KATP-channel hyperinsulinism—dominant SUR1.” These names all refer to the same idea: a dominant ABCC8/SUR1 problem leading to recurrent hypoglycemia. Orpha+1

---

Types

Clinicians usually sort KATP hyperinsulinism by gene (ABCC8/SUR1 vs. KCNJ11/Kir6.2), inheritance (dominant vs. recessive), anatomy (diffuse vs. focal), and drug response (diazoxide-responsive vs. unresponsive). The autosomal dominant SUR1 form is typically diffuse and diazoxide-responsive with a milder phenotype than recessive KATP disease, though exceptions exist. Focal disease and severe diazoxide-unresponsive forms are more often tied to recessive or focal mechanisms, not classic dominant SUR1—yet rare dominant SUR1 mutations with poor drug response have been reported. OUP Academic+3Orpha+3BioMed Central+3

---

Causes

In a genetic condition, “causes” naturally center on the gene and channel biology. To be practical for families and clinicians, the list below mixes primary causes (the gene/channel) and common clinical drivers that bring on or reveal hypoglycemia (fasting, illness, etc.). Each item is one short idea in plain English, with the science behind it.

1. A heterozygous pathogenic ABCC8 (SUR1) variant that reduces KATP channel activity is the core cause; one changed copy is enough. Orpha+1

2. Dominant-negative SUR1 effects (a faulty subunit impairing the whole channel) can further blunt channel opening and exaggerate insulin release. OUP Academic

3. Missense ABCC8 variants that alter SUR1 gating keep the channel too closed and push insulin up. OUP Academic

4. Splice or truncating variants can reduce functional SUR1 protein, lowering channel numbers on the beta-cell surface. PubMed

5. Energy-sensing failure of the KATP brake: the beta cell does not read ATP/ADP correctly, so it keeps secreting insulin. MedlinePlus

6. Diazoxide mechanism mismatch: many dominant SUR1 cases respond to diazoxide (which opens KATP), but a few rare dominant SUR1 mutations blunt drug response, so episodes persist. Orpha+1

7. Prolonged fasting removes the normal glucose supply, and the “over-insulin” state drives sugar even lower. NCBI

8. Intercurrent illness (fever, infections) increases glucose needs; relative insulin excess then triggers dips. NCBI

9. Missed feeds in infants are a common setting where the condition first shows as jitteriness or lethargy. NCBI

10. Post-exercise periods (older children/adults) can unmask low sugar because muscles used glucose and insulin remains inappropriately high. NCBI

11. High carbohydrate boluses can cause rebound lows when insulin secretion overshoots and then outlasts the food. BioMed Central

12. Birth/perinatal stress: big insulin swings around birth can reveal the condition (e.g., neonatal hypoglycemia). BioMed Central

13. Family history of ABCC8 hyperinsulinism increases likelihood in offspring due to dominant inheritance. Orpha

14. Diffuse beta-cell involvement (typical of dominant disease) means the whole pancreas contributes, not just a spot. Orpha

15. Variable expressivity: some relatives have mild, late-onset episodes; others present in infancy. Orpha

16. Progression risk across life: some with ABCC8 variants show a long-term shift from hypoglycemia to impaired glucose tolerance or even diabetes as beta-cell function changes. PMC+2PMC+2

17. Medication interactions (e.g., drugs that increase insulin effect or reduce glucose) can expose the underlying tendency to low sugar. NCBI

18. Poor glycogen stores in small infants make them less able to buffer insulin-driven falls in glucose. NCBI

19. Inadequate counter-regulation (muted ketones and free fatty acids during episodes) removes the brain’s backup fuels. NCBI

20. Lack of timely diagnosis: untreated recurrent hypoglycemia begets more episodes and neurological risk. Early recognition of ABCC8 disease prevents harm. NCBI+1

---

Symptoms

1) Jitteriness and tremor are common early signs of low sugar in newborns and infants. They can be brief or recurrent. NCBI

2) Lethargy or unusual sleepiness happens because the brain depends on steady glucose to stay alert. NCBI

3) Poor feeding or trouble finishing feeds occurs when the brain senses low fuel and lowers arousal and appetite. NCBI

4) Cyanosis or pallor can accompany severe dips when stress hormones surge during hypoglycemia. NCBI

5) Irritability is a nonspecific but frequent sign; infants may cry and settle only after glucose improves. NCBI

6) Sweating reflects autonomic activation during low sugar and may be prominent during sleep. NCBI

7) Rapid breathing may appear with stress hormones and lactate changes when glucose is low. NCBI

8) Seizures can occur in deeper or prolonged hypoglycemia and require urgent correction to protect the brain. NCBI

9) Developmental delay or learning difficulties may follow repeated untreated episodes in infancy; prevention is the goal. NCBI+1

10) Hypotonia (low muscle tone) can be seen during episodes because neurons lack fuel. NCBI

11) Headache in older children/adults may signal a drop, especially with fasting or after exercise. NCBI

12) Dizziness or faintness reflects the brain’s immediate need for glucose. NCBI

13) Visual blurring can occur during acute lows and clears as glucose normalizes. NCBI

14) Macro-sized newborn (macrosomia) is sometimes noted in hyperinsulinism states because fetal insulin is a growth factor. BioMed Central

15) Long-term shift to higher glucose (some adults): a subset with ABCC8 variants later shows impaired glucose tolerance or diabetes. PMC+1

---

Diagnostic tests

A) Physical exam (what clinicians look for at the bedside)

1) General neurological check (alertness, tone, seizures): Doctors assess arousal, tone, reflexes, and seizure activity because the brain is most sensitive to low sugar. Abnormal findings push urgent glucose testing and treatment. NCBI

2) Growth pattern and birth size: A history of a large newborn or feeding problems may suggest longstanding excess insulin. This guides early screening and safety planning. BioMed Central

3) Autonomic signs (sweating, pallor, fast heart rate): These bedside clues often appear before a meter reading is available and prompt immediate glucose checks. NCBI

4) Family history review: Dominant inheritance means one affected parent or multiple relatives may report “low sugar” spells, guiding genetic testing. Orpha

5) Illness/exercise triggers: Taking a focused history (fasting tolerance, illness, exertion) helps unmask ABCC8 disease patterns. NCBI

B) “Manual” or bedside tests (done quickly to confirm a low)

6) Capillary/venous glucose measurement: The essential first step is to confirm low plasma glucose and treat immediately if very low or symptomatic. NCBI

7) Supervised fasting test (in hospital): Under careful monitoring, clinicians observe if insulin stays inappropriately high as glucose falls—classic for hyperinsulinism. NCBI

8) Bedside glucagon challenge during hypoglycemia: A rapid rise in glucose after glucagon suggests insulin was suppressing the body’s own glucose release, supporting hyperinsulinism. NCBI

9) Point-of-care ketone check: Low or absent ketones during hypoglycemia implies insulin is too high, because insulin blocks fat breakdown and ketone production. NCBI

10) Bedside lactate and vitals: These help rule out other causes and quantify stress response during an episode. NCBI

C) Lab and pathological tests (the core biochemical work-up)

11) “Critical sample” labs during a spontaneous low: Insulin, C-peptide, beta-hydroxybutyrate (ketones), free fatty acids, cortisol, and growth hormone are drawn during hypoglycemia. Detectable insulin with suppressed ketones/FFAs strongly supports hyperinsulinism. NCBI

12) Response to controlled glucagon in the lab: A strong glucose rise confirms that hepatic glycogen was “locked away” by excess insulin. NCBI

13) Genetic testing for ABCC8: Sequencing and copy-number analysis look for a single, disease-causing variant consistent with autosomal dominant SUR1 deficiency. Family testing clarifies inheritance. Orpha

14) Broader monogenic hypoglycemia panel: If ABCC8 testing is negative or unclear, panels include KCNJ11 and other genes to cover overlapping KATP disorders. NCBI

15) Drug-response assessment (diazoxide trial): Many dominant SUR1 cases improve on diazoxide, a KATP opener; a poor response suggests atypical variants or different mechanisms and guides imaging or surgery decisions. Orpha+1

D) Electrodiagnostic tests (brain safety)

16) EEG during or after seizures: EEG documents seizure activity from low glucose and helps track recovery after stabilization; it also helps rule out primary epilepsy. NCBI

17) Neurodevelopmental screening tools: Formal developmental evaluations monitor milestones in infants with a history of severe or recurrent lows, to catch and address delays early. NCBI

E) Imaging tests (to sort diffuse vs focal and plan treatment)

18) 18F-DOPA PET/CT of the pancreas: This scan helps distinguish focal lesions (often surgical) from diffuse disease (medical). Dominant SUR1 disease is usually diffuse, but imaging helps if the course is atypical. BioMed Central

19) Pancreatic MRI/ultrasound (limited): These are usually less sensitive than 18F-DOPA PET for hyperinsulinism, but may be used contextually to exclude other structural issues. BioMed Central

20) Ancillary brain MRI (when indicated): If neurological symptoms are significant or prolonged, brain MRI checks for injury from previous severe hypoglycemia. Prevention of such injury is the central goal of early diagnosis. NCBI

Non-pharmacological treatments (therapies & other measures)

(Each item explains the what, purpose, and mechanism in easy words.)

1. Fast, consistent treatment of low sugars with IV dextrose when needed
   What: In hospital, doctors give sugar (glucose) through a vein.
   Purpose: Quickly raise blood sugar to a safe level.
   Mechanism: Directly supplies glucose to blood, bypassing the gut. (Guidelines suggest an initial bolus ~200 mg/kg of 10% dextrose followed by infusion tailored to keep glucose normal.) PMC

2. Frequent feeds (daytime) and planned overnight nutrition
   What: Small, regular feeds of breast milk/formula/food.
   Purpose: Prevent long fasting gaps that trigger lows.
   Mechanism: Keeps a steady stream of carbohydrates entering the blood. PMC

3. Uncooked cornstarch (for older infants/children only, under specialist advice)
   What: A slow-release carbohydrate taken at bedtime or before longer fasts.
   Purpose: Extend time between feeds and reduce overnight lows.
   Mechanism: Cornstarch digests slowly, steadily releasing glucose for hours; typical reported doses are ~1–2 g/kg in children >9 months (evidence is limited—must be individualized). PMC+1

4. Enteral feeding support (NG tube / gastrostomy in severe cases)
   What: A tube to deliver measured carbohydrates if oral intake is unreliable.
   Purpose: Ensure safe, continuous nutrition.
   Mechanism: Delivers planned carbs even during illness or poor intake. e-apem.org

5. Emergency glucagon plan at home
   What: Families trained to give glucagon for severe symptomatic lows.
   Purpose: Rapid self-rescue when the child cannot take sugar by mouth.
   Mechanism: Glucagon releases stored liver glucose to raise blood sugar. (FDA labels describe dosing instructions and indications for severe hypoglycemia; HI use is off-label.) FDA Access Data

6. 40% oral dextrose gel for newborns (in hospital protocols)
   What: Sugar gel massaged into the cheek as part of a feeding plan.
   Purpose: Treat mild-to-moderate neonatal hypoglycemia and reduce IV use.
   Mechanism: Buccal absorption plus enteral absorption rapidly lifts glucose. NCBI+1

7. Continuous glucose monitoring (CGM) when appropriate
   What: A small sensor that reads glucose trends.
   Purpose: Early detection of falling sugars and prevention of severe events.
   Mechanism: Frequent readings and alarms prompt timely carbs or meds. (Supported as a practical tool in many centers; integrate with clinical judgment.) Children’s Hospital of Philadelphia

8. Sick-day rules
   What: Extra carbohydrates and closer monitoring during illness.
   Purpose: Prevent hypoglycemia when appetite is poor or demands change.
   Mechanism: Preemptive carbs and more checks counter higher risk of lows. PMC

9. Exercise timing & snacks
   What: Pre-exercise carbs and carrying fast-acting glucose.
   Purpose: Avoid activity-related drops in glucose.
   Mechanism: Carbs taken before/during activity match the extra sugar use. PMC

10. School/daycare care plan
    What: Written steps for checking, treating, and documenting lows.
    Purpose: Keep the child safe outside home.
    Mechanism: Trained staff act early and correctly per plan. PMC

11. Caregiver education & emergency letter
    What: Teach signs of hypoglycemia and rapid treatment steps.
    Purpose: Fast, confident action reduces brain-injury risk.
    Mechanism: Knowledge shortens time to treatment. Pediatric Endocrine Society

12. Home ketone and glucose testing
    What: Check glucose and, sometimes, ketones during illness/overnight.
    Purpose: Detect unsafe lows early.
    Mechanism: Objective numbers prompt timely carbs or medical review. PMC

13. Avoid prolonged fasting (e.g., before procedures)
    What: Minimize “NPO” time; use IV dextrose if needed.
    Purpose: Prevent peri-procedural hypoglycemia.
    Mechanism: Continuous glucose supply when not eating. PMC

14. Nutrition with balanced protein/fat with carbs
    What: Add protein/fat to slow digestion of carbs (dietitian-led).
    Purpose: Reduce rapid glucose dips after meals.
    Mechanism: Mixed meals slow gastric emptying and glucose swings. PMC

15. Nighttime safety checks
    What: Extra checks or CGM alarms overnight in prone patients.
    Purpose: Catch nocturnal lows early.
    Mechanism: Timed prompts + backup carbs prevent severe episodes. Children’s Hospital of Philadelphia

16. 18F-DOPA PET/CT (only when surgery is considered)
    What: Imaging to find a focal pancreatic lesion if genetics/clinical picture suggest it.
    Purpose: If focal disease is present, limited surgery can cure.
    Mechanism: The tracer highlights overactive beta-cell clusters. PubMed+1

17. Genetic testing & counseling
    What: Confirm ABCC8 variant and inheritance pattern.
    Purpose: Guides therapy (e.g., diazoxide responsiveness) and family planning.
    Mechanism: Knowing the exact mutation refines risk and treatment choices. NCBI

18. Multidisciplinary HI center follow-up
    What: Endocrinologist, dietitian, radiology, and surgery teams.
    Purpose: Reduce hypoglycemia exposure and avoid unnecessary surgery.
    Mechanism: Coordinated protocols and rapid adjustments. PMC

19. Neurodevelopmental surveillance
    What: Early assessment and therapy if delays emerge.
    Purpose: Hypoglycemia can affect brain development if not managed.
    Mechanism: Early therapy improves outcomes. Pediatric Endocrine Society

20. Surgery only for carefully selected cases
    What: Limited resection for proven focal disease; avoid near-total pancreatectomy in diffuse, diazoxide-responsive dominant ABCC8 when possible.
    Purpose: Cure focal disease; avoid long-term diabetes from large resections.
    Mechanism: Remove only the overactive focus; preserve pancreas. PubMed+1

---

Drug treatments

Important: In the U.S., diazoxide is the only FDA-approved drug that directly targets hyperinsulinemic hypoglycemia. Most other medicines below are used off-label in HI to reduce insulin release or support glucose. I cite the FDA label for authoritative dosing/safety; if the label’s indication is different, I say so.

1. Diazoxide (Proglycem®) — approved for hypoglycemia due to hyperinsulinism
   Class: Potassium-channel opener.
   Typical pediatric dose: ~5–15 mg/kg/day orally in divided doses (specialist adjusts).
   When to give: Ongoing, if responsive; effect assessed over days.
   Purpose/Mechanism: Keeps K_ATP channels open via SUR1, reducing insulin release.
   Key side effects: Fluid retention/edema, hypertrichosis; rare pulmonary hypertension (FDA warning). Source: FDA label. FDA Access Data+1

2. Hydrochlorothiazide or chlorothiazide — adjunct, off-label in HI
   Class: Thiazide diuretic.
   Dose/Time: Low doses with diazoxide as needed.
   Purpose/Mechanism: Treats diazoxide-related fluid retention; mild hyperglycemic effect by reducing insulin release sensitivity. Source: Clinical reviews; use guided by the diazoxide label’s edema risk. U.S. Food and Drug Administration+1

3. Octreotide (Sandostatin®) — off-label for HI
   Class: Somatostatin analog.
   Dose: Short-acting SQ titration (specialist dosing; labels detail acromegaly/VIPoma dosing).
   When: If diazoxide is ineffective/contraindicated.
   Purpose/Mechanism: Inhibits insulin secretion via somatostatin receptors on beta cells.
   Key risks: Gallstones, GI upset, thyroid effects; monitor growth and nutrition. Source: FDA labels. FDA Access Data+1

4. Octreotide LAR (Sandostatin LAR Depot®) — off-label for HI
   Class: Long-acting somatostatin analog.
   Dose/Time: IM every 4 weeks (label gives regimens for labeled indications).
   Purpose/Mechanism: Long-term insulin suppression in patients stabilized on short-acting octreotide. Source: FDA label. FDA Access Data

5. Lanreotide (Somatuline Depot® / Lanreotide Injection) — off-label for HI
   Class: Long-acting somatostatin analog.
   Dose/Time: Typically 120 mg deep SQ every 4 weeks per label (for labeled indications).
   Purpose/Mechanism: Sustained somatostatin receptor activation to reduce insulin release.
   Key risks: GI effects, gallstones; monitor glucose. Source: FDA labels. FDA Access Data+1

6. Pasireotide (Signifor® / Signifor LAR®) — off-label in HI
   Class: Broader-spectrum somatostatin analog (SSTR1–5).
   Dose/Time: SC BID (Signifor) or IM q4wk (Signifor LAR) per label for Cushing’s/acromegaly.
   Purpose/Mechanism: Potent inhibition of insulin; sometimes used in refractory HI.
   Key risks: Can cause hyperglycemia; monitor closely. Source: FDA labels. FDA Access Data+1

7. Glucagon for injection — off-label chronic use in HI; on-label for severe hypoglycemia
   Class: Counter-regulatory hormone.
   Dose/Time: Rescue 0.5–1 mg IM/SQ for severe lows; infusion in hospital per specialist.
   Purpose/Mechanism: Mobilizes liver glucose rapidly.
   Risks: Nausea, vomiting; rare hypersensitivity. Source: FDA label. FDA Access Data

8. Sirolimus (Rapamune®) — off-label in severe refractory HI
   Class: mTOR inhibitor (immunosuppressant).
   Dose/Time: Trough-guided per label (approved for renal transplant).
   Purpose/Mechanism: mTOR pathway modulation may dampen beta-cell overactivity; reserved for specialized centers because of immunosuppression risks. Source: FDA label. FDA Access Data

9. Everolimus (Afinitor® / Afinitor Disperz®) — off-label in refractory HI
   Class: mTOR inhibitor.
   Dose/Time: Label gives indication-specific dosing; if used for HI, it’s specialist-directed and off-label.
   Purpose/Mechanism: Similar to sirolimus; consider only when benefits outweigh risks. Source: FDA labels. FDA Access Data

10. Nifedipine (Procardia®/Procardia XL®) — rare, off-label in HI
    Class: Calcium-channel blocker.
    Dose/Time: Label provides doses for hypertension/angina; any HI use is experimental.
    Purpose/Mechanism: May reduce insulin secretion by calcium-influx blockade, but evidence is weak and inconsistent; not a first-line option. Source: FDA labels. FDA Access Data+1

11. Dextrose (glucose) IV infusion — supportive
    Class: Carbohydrate (parenteral nutrition/IV fluid).
    Dose/Time: Titrated to keep plasma glucose in target per guidelines.
    Purpose/Mechanism: Direct glucose delivery to maintain normoglycemia while other therapies act. Source: International guidelines. PMC

12. Diazoxide choline ER (Vykat XR™) — different indication
    Class: Diazoxide formulation.
    Note: Recently approved for Prader-Willi syndrome–related hyperphagia, not HI; included here only to avoid confusion with Proglycem. Source: Label and approval summaries; not a replacement for Proglycem in HI. FDA Access Data

13. Adjunct diuretics (to manage edema from diazoxide) — supportive
    Class: Thiazides as above.
    Purpose/Mechanism: Counter fluid retention; helps continue effective diazoxide therapy. Source: FDA safety communication + reviews. U.S. Food and Drug Administration+1

14. Antiemetics, PPIs, or other symptomatic meds — supportive
    Used to manage GI side effects of somatostatin analogs as needed, per labels. FDA Access Data

15. Bile-acid therapy if gallstones form on somatostatin analogs — supportive
    Gallstone risk is highlighted in octreotide labels; manage per standard guidelines. FDA Access Data

---

Dietary molecular supplement options

These are nutrition tools, not medications; dosing is individualized. Evidence is strongest for hospital glucose protocols and for frequent feeding. Cornstarch has limited but practical support; other items below are adjuncts to help keep glucose steady.

1. Uncooked cornstarch (≥9 months old): 1–2 g/kg before bedtime or longer fasts; slow glucose release for hours; watch for GI intolerance; evidence limited but used pragmatically. PMC+1

2. Rapid glucose sources (oral glucose gel/solutions): Small measured doses for mild dips; fast mucosal and enteral absorption. (Neonatal gel protocols specify 40% gel 0.5 mL/kg as part of care pathways.) NCBI

3. Low-glycemic, complex carbs with protein/fat: Balanced meals slow glucose swings compared with simple sugars alone. PMC

4. Bedtime snack with complex carb + protein: Extends overnight stability (dietitian-planned). PMC

5. Illness-day oral rehydration with added carbs: Keeps intake steady when appetite is low. PMC

6. Enteral formulas with complex carbs: For children needing tube feeds to ensure steady glucose delivery. e-apem.org

7. Measured fruit juice or glucose tabs for symptomatic lows: Quick correction when awake and safe to swallow. PMC

8. Starch-based overnight regimens (specialist-supervised): Structured timing/amounts to match prior hypoglycemia patterns. PMC

9. Avoid “sugar only” grazing: Pair carbs with protein/fat to limit rebound lows. PMC

10. Dietitian-guided calorie distribution: Aligns intake with activity and sleep to prevent long gaps. PMC

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved stem-cell or “regenerative” drugs for congenital hyperinsulinism. The FDA explicitly warns patients to avoid unapproved stem-cell/exosome products because they are illegal and have caused serious harm (infections, blindness). Please do not seek these for HI outside legitimate clinical trials and ethics-approved research. U.S. Food and Drug Administration+1

---

Surgeries (what’s done and why)

1. Focal lesionectomy (limited pancreatic resection)
   What: Remove only the small overactive spot (focus) of beta cells.
   Why: Curative in most focal HI when correctly localized by 18F-DOPA PET/CT. PubMed+1

2. Segmental/distal pancreatectomy (limited)
   What: Remove the involved segment if focal site is in tail/body.
   Why: Preserve as much pancreas as possible; lower diabetes risk vs extensive resection. OUP Academic

3. Intraoperative frozen-section guidance
   What: Pathology confirms margins to ensure the focus is fully removed.
   Why: Maximizes chance of cure while sparing normal tissue. PubMed

4. Near-total pancreatectomy (95–98%)
   What: Large resection for diffuse disease only when medical therapy fails.
   Why: Reduce severe, persistent hypoglycemia; however, many children later develop diabetes and exocrine insufficiency—so this is a last resort. PLOS+1

5. Laparoscopic approach when feasible
   What: Minimally invasive technique for selected cases at experienced centers.
   Why: Comparable pancreatic outcomes with less incision morbidity in expert hands. clinicofsurgery.org

---

Prevention tips

1. Never skip scheduled feeds; avoid long fasts. PMC

2. Keep fast-acting glucose on hand (at home/school/travel). FDA Access Data

3. Use a written action plan for lows; train all caregivers. Pediatric Endocrine Society

4. Consider CGM with alarms if your team recommends it. Children’s Hospital of Philadelphia

5. Extra monitoring during illness; act early with carbs. PMC

6. Coordinate procedure fasting with your team; use IV dextrose if needed. PMC

7. Balance meals (carb + protein/fat) to reduce swings. PMC

8. Plan snacks around exercise or long car trips. PMC

9. Keep an emergency glucagon kit and know how to use it. FDA Access Data

10. Maintain regular specialist follow-up (endocrine/dietitian). PMC

---

When to see a doctor

• Immediately if there’s seizure, unresponsiveness, or repeated sugars below your care plan’s threshold despite oral glucose—use glucagon and call emergency services. FDA Access Data

• Urgently if frequent symptomatic lows occur, your child cannot keep fluids down, there’s illness with poor intake, or the CGM shows recurrent nighttime hypoglycemia. PMC

• Promptly if new side effects appear after starting diazoxide (e.g., swelling, breathing trouble) or somatostatin analogs (e.g., severe abdominal pain—possible gallstones). U.S. Food and Drug Administration+1

---

What to eat and what to avoid

1. Eat: Regular, balanced meals with complex carbs + protein/fat. Avoid: Long gaps without food. PMC

2. Eat: Bedtime snack if advised. Avoid: Going to bed hungry. PMC

3. Use (older infants/children): Uncooked cornstarch under specialist guidance. Avoid: Using it in babies <9 months. Congenital Hyperinsulinism International

4. Use: Fast-acting glucose (tablets/gel/juice) for symptoms. Avoid: Very high-sugar drinks as routine snacks between meals. NCBI

5. Eat: Extra carbs during illness or heavy activity. Avoid: Skipping planned illness-day carbs. PMC

6. Use: Dietitian-directed total calories for age/weight. Avoid: Unsupervised restrictive diets. PMC

7. Consider: Fiber-rich carbs that digest slowly. Avoid: Large solo sugar loads that may rebound low. PMC

8. Maintain: Good hydration. Avoid: Caffeine/energy drinks for children. PMC

9. Plan: Portable snacks for trips. Avoid: Fasting on long car or clinic days. PMC

10. Coordinate: Any special formulas/feeds with your team. Avoid: Internet “cures” or unapproved supplements. e-apem.org

---

FAQs

1. Is autosomal dominant ABCC8-HI usually milder?
   Often yes, and many are diazoxide-responsive—though exceptions exist. NCBI+1

2. How is the diagnosis confirmed?
   By documenting hypoglycemia with inappropriately high insulin action (low ketones/free fatty acids, rise in glucose after glucagon) and genetic testing showing an ABCC8 variant. PMC

3. What’s the first-line medicine?
   Diazoxide (the only U.S. drug specifically labeled for hyperinsulinemic hypoglycemia). FDA Access Data

4. What if diazoxide doesn’t work or causes edema?
   Doctors may add a thiazide diuretic for edema, or switch to somatostatin analogs (off-label). U.S. Food and Drug Administration+1

5. Are somatostatin analogs safe for kids?
   They can help, but need monitoring (gallstones, GI effects, growth). Decisions are specialist-led. FDA Access Data

6. When is surgery needed?
   If a focal lesion is proven (genetics suggest focality; 18F-DOPA PET/CT localizes it); limited surgery is often curative. PubMed+1

7. Is near-total pancreatectomy a cure for diffuse disease?
   It lowers hypoglycemia risk but many children later develop diabetes and exocrine insufficiency, so it’s a last resort. PLOS

8. Can CGM prevent severe lows?
   It helps detect trends and alarms early, but it’s one tool in a broader plan. Children’s Hospital of Philadelphia

9. Does uncooked cornstarch always work?
   No. It may help some older children overnight, but evidence is limited and dosing is individualized. PMC

10. Is glucagon safe at home?
    Yes when used correctly for severe lows; training is essential. FDA Access Data

11. Are there stem-cell cures I can buy?
    No. The FDA warns against unapproved stem-cell treatments; they can be dangerous. U.S. Food and Drug Administration

12. What causes brain injury risk in HI?
    Repeated or severe hypoglycemia, especially in early life. Prevention and rapid treatment matter. Pediatric Endocrine Society

13. Can children outgrow HI?
    Some milder forms improve with age; ongoing follow-up decides when to taper therapy. NCBI

14. Are mTOR inhibitors common for HI?
    No; they’re off-label and reserved for refractory cases at experienced centers. FDA Access Data+1

15. Who should manage HI care?
    A pediatric endocrine team experienced in HI, ideally in or linked to a specialized center. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 02, 2025.

PDF Documents For This Disease Condition References